Challenges and opportunities of metabolomics

Journal of Cellular Physiology

Volumn 227, Issue 8, 2012, Pages 2975-2981

  Johnson, Caroline H ^a   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PARACETAMOL; STABLE ISOTOPE;

ANALYTICAL EQUIPMENT; CAPILLARY ELECTROPHORESIS; CARBON NUCLEAR MAGNETIC RESONANCE; DIETARY INTAKE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; EXPERIMENTAL DESIGN; GAS CHROMATOGRAPHY; GENETIC DIFFERENCE; GENOMICS; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; INTESTINE FLORA; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITE; METABOLOME; METABOLOMICS; MOLECULAR WEIGHT; NANOSTRUCTURE INITIATOR MASS SPECTROMETRY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOMETABOLOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; SHORT SURVEY; SURVIVAL; TIME OF FLIGHT MASS SPECTROMETRY; TRANSCRIPTOMICS; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL MARKERS; BODY FLUIDS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MICE;

EID: 84858730393     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24002     Document Type: Short Survey

References (87)

1. Arn PH. 2007. Newborn screening: Current status. Health Aff (Millwood) 26: 559-566.
2. Babushok VI, Linstrom PJ, Reed JJ, Zenkevich IG, Brown RL, Mallard WG, Stein SE. 2007. Development of a database of gas chromatographic retention properties of organic compounds. J Chromatogr A 1157: 414-421.
3. Bino RJ, Hall RD, Fiehn O, Kopka J, Saito K, Draper J, Nikolau BJ, Mendes P, Roessner-Tunali U, Beale MH, Trethewey RN, Lange BM, Wurtele ES, Sumner LW. 2004. Potential of metabolomics as a functional genomics tool. Trends Plant Sci 9: 418-425.
4. Bonzo JA, Patterson AD, Krausz KW, Gonzalez FJ. 2010. Metabolomics identifies novel Hnf1{alpha}-dependent physiological pathways in vivo. Mol Endocrinol 24: 2343-2355.
5. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. 2002. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8: 1439-1444.
6. Castro-Perez JM, Roddy TP, Shah V, Wang SP, Ouyang X, Ogawa A, McLaren DG, Tadin-Strapps M, Robinson MJ, Bartz SR, Ason B, Chen Y, Previs SF, Wong KK, Vreeken RJ, Johns DG, Hubbard BK, Hankemeier T, Mitnaul L. 2011. Attenuation of Slc27a5 gene expression followed by LC-MS measurement of bile acid reconjugation using metabolomics and a stable isotope tracer strategy. J Proteome Res 10: 4683-4691.
7. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC. 2009. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8: 352-361.
8. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, Gonzalez FJ. 2006. Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 318: 1330-1342.
9. Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, Felton JS, Idle JR, Gonzalez FJ. 2007. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol 20: 531-542.
10. Chen C, Krausz KW, Idle JR, Gonzalez FJ. 2008. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 283: 4543-4559.
11. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. 2005. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65: 3030-3034.
12. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. 2009. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 37: 1611-1621.
13. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ. 2010. Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335: 32-41.
14. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, Gonzalez FJ. 2005a. Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18: 1471-1478.
15. Cheung C, Yu AM, Ward JM, Krausz KW, Akiyama TE, Feigenbaum L, Gonzalez FJ. 2005b. The cyp2e1-humanized transgenic mouse: Role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos 33: 449-457.
16. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. 2006. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
17. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. 2009. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106: 14728-14733.
18. Cloarec O, Dumas ME, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, Gauguier D, Lindon JC, Holmes E, Nicholson J. 2005. Statistical total correlation spectroscopy: An exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 77: 1282-1289.
19. D'Agostino LA, Lam KP, Lee R, Britz-McKibbin P. 2011. Comprehensive plasma thiol redox status determination for metabolomics. J Proteome Res 10: 592-603.
20. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H, Gomez-Lechon MJ, Pelkonen O. 2000. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 28: 1321-1326.
21. Dunn WB. 2008. Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes. Phys Biol 5: 011001.
22. Fan TW, Lane AN, Higashi RM, Bousamra M, II, Kloecker G, Miller DM. 2009a. Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol 87: 83-86.
23. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. 2009b. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 8: 41.
24. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. 2010. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 5: 1-10.
25. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. 2000. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: Application to the C57BL10J and Alpk: ApfCD mouse. FEBS Lett 484: 169-174.
26. Gika HG, Theodoridis GA, Wilson ID. 2008. Hydrophilic interaction and reversed-phase ultra-performance liquid chromatography TOF-MS for metabonomic analysis of Zucker rat urine. J Sep Sci 31: 1598-1608.
27. Gingell R, Bridges JW, Williams RT. 1971. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica 1: 143-156.
28. Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ. 2006. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol 19: 818-827.
29. Giri S, Krausz KW, Idle JR, Gonzalez FJ. 2007. The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem Pharmacol 73: 561-573.
30. Greving MP, Patti GJ, Siuzdak G. 2011. Nanostructure-initiator mass spectrometry metabolite analysis and imaging. Anal Chem 83: 2-7.
31. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. 2011. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7: 267-286.
32. Hardy N, Jenkins H. 2010. Reporting standards. In: Neilsen J, Jewett MC, editors. Metabolomics: A powerful tool in systems biology. Berlin: Springer. pp 53-73.
33. Heinemann M, Zenobi R. 2011. Single cell metabolomics. Curr Opin Biotechnol 22: 26-31.
34. Jenkins H, Hardy N, Beckmann M, Draper J, Smith AR, Taylor J, Fiehn O, Goodacre R, Bino RJ, Hall R, Kopka J, Lane GA, Lange BM, Liu JR, Mendes P, Nikolau BJ, Oliver SG, Paton NW, Rhee S, Roessner-Tunali U, Saito K, Smedsgaard J, Sumner LW, Wang T, Walsh S, Wurtele ES, Kell DB. 2004. A proposed framework for the description of plant metabolomics experiments and their results. Nat Biotechnol 22: 1601-1606.
35. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM. 2011. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89: 97-104.
36. Johnson CH, Athersuch TJ, Wilson ID, Iddon L, Meng X, Stachulski AV, Lindon JC, Nicholson JK. 2008. Kinetic and J-resolved statistical total correlation NMR spectroscopy approaches to structural information recovery in complex reacting mixtures: Application to acyl glucuronide intramolecular transacylation reactions. Anal Chem 80: 4886-4895.
37. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. 2011a. Xenobiotic metabolomics: Major impact on the metabolome. Annu Rev Pharmacol Toxicol In press.
38. Johnson CH, Patterson AD, Krausz KW, Lanz C, Kang DW, Luecke H, Gonzalez FJ, Idle JR. 2011b. Radiation metabolomics. 4. UPLC-ESI-QTOFMS-based metabolomics for urinary biomarker discovery in gamma-irradiated rats. Radiat Res 175: 473-484.
39. Kassis AI, Yongliang YS, Adelstein J. 2010. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn 10: 65-74.
40. 13C NMR spectroscopy of urine for metabonomic studies. Anal Chem 74: 4588-4593.
41. Kiani J, Imam SZ. 2007. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 6: 33.
42. Kind T, Wohlgemuth G, Lee do Y, Lu Y, Palazoglu M, Shahbaz S, Fiehn O. 2009. FiehnLib: Mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem 81: 10038-10048.
43. Kinross JM, Holmes E, Darzi AW, Nicholson JK. 2011. Metabolic phenotyping for monitoring surgical patients. Lancet 377: 1817-1819.
44. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM, Brindle KM, Metcalfe JC. 2006. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 12: 705-710.
45. Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmuller E, Dormann P, Weckwerth W, Gibon Y, Stitt M, Willmitzer L, Fernie AR, Steinhauser D. 2005. GMD@CSB. DB: The Golm Metabolome Database. Bioinformatics 21: 1635-1638.
46. Lane AN, Fan TW, Bousamra M, II, Higashi RM, Yan J, Miller DM. 2011. Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS 15: 173-182.
47. Lanz C, Patterson AD, Slavik J, Krausz KW, Ledermann M, Gonzalez FJ, Idle JR. 2009. Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. Radiat Res 172: 198-212.
48. Lee R, Britz-McKibbin P. 2010. Metabolomic studies of radiation-induced apoptosis of human leukocytes by capillary electrophoresis-mass spectrometry and flow cytometry: Adaptive cellular responses to ionizing radiation. Electrophoresis 31: 2328-2337.
49. Ley RE. 2010. Obesity and the human microbiome. Curr Opin Gastroenterol 26: 5-11.
50. Li F, Patterson AD, Hofer CC, Krausz KW, Gonzalez FJ, Idle JR. 2010. Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol 80: 1063-1074.
51. Li F, Patterson AD, Hofer CC, Krausz KW, Gonzalez FJ, Idle JR. 2011. A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol 81: 1043-1053.
52. Lindon JC, Nicholson JK, Holmes E, Keun HC, Craig A, Pearce JT, Bruce SJ, Hardy N, Sansone SA, Antti H, Jonsson P, Daykin C, Navarange M, Beger RD, Verheij ER, Amberg A, Baunsgaard D, Cantor GH, Lehman-McKeeman L, Earll M, Wold S, Johansson E, Haselden JN, Kramer K, Thomas C, Lindberg J, Schuppe-Koistinen I, Wilson ID, Reily MD, Robertson DG, Senn H, Krotzky A, Kochhar S, Powell J, van der Ouderaa F, Plumb R, Schaefer H, Spraul M. 2005. Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol 23: 833-838.
53. Liu A, Patterson AD, Yang Z, Zhang X, Liu W, Qiu F, Sun H, Krausz KW, Idle JR, Gonzalez FJ, Dai R. 2009. Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos 37: 1157-1163.
54. Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ. 2008a. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology 149: 1869-1879.
55. Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ. 2008b. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36: 2506-2512.
56. Manna SK, Patterson AD, Yang Q, Krausz KW, Li H, Idle JR, Fornace AJ, Jr., Gonzalez FJ. 2010. Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. J Proteome Res 9: 4176-4188.
57. Manna SK, Patterson AD, Yang Q, Krausz KW, Idle JR, Fornace AJ, Gonzalez FJ. 2011. UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model. J Proteome Res 10: 4120-4133.
58. Marriott P, Shellie R. 2002. Principles and applications of comprehensive two-dimensional gas chromatography. Trend Anal Chem 21: 573-583.
59. Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, Zirah S, Murphy GM, Cloarec O, Lindon JC, Sprenger N, Fay LB, Kochhar S, van Bladeren P, Holmes E, Nicholson JK. 2007. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol 3: 112.
60. Mikov M, Caldwell J, Dolphin CT, Smith RL. 1988. The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol. Studies in neomycin-pretreated and germ-free mice. Biochem Pharmacol 37: 1445-1449.
61. Moka D, Vorreuther R, Schicha H, Spraul M, Humpfer E, Lipinski M, Foxall PJ, Nicholson JK, Lindon JC. 1998. Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 17: 125-132.
62. Nicholson JK, Holmes E. 2006. Global systems biology and personalized healthcare solutions. Discov Med 6: 63-70.
63. Nicholson JK, Lindon JC, Wilson ID. 2011. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12: 103-111.
64. Northen TR, Yanes O, Northen MT, Marrinucci D, Uritboonthai W, Apon J, Golledge SL, Nordstrom A, Siuzdak G. 2007. Clathrate nanostructures for mass spectrometry. Nature 449: 1033-1036.
65. Northen TR, Lee JC, Hoang L, Raymond J, Hwang DR, Yannone SM, Wong CH, Siuzdak G. 2008. A nanostructure-initiator mass spectrometry-based enzyme activity assay. Proc Natl Acad Sci USA 105: 3678-3683.
66. Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ. 2011. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 41: 112-123.
67. Patterson A, Li H, Eichler G, Krausz K, Weinstein J, Fornace AJ, Gonzalez F, Idle J. 2008. UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80: 665-674.
68. Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ. 2011. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 286: 19511-19522.
69. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S. 2009. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27: 439-445.
70. Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG. 2005. Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol Sci 87: 277-284.
71. Spagou K, Wilson ID, Masson P, Theodoridis G, Raikos N, Coen M, Holmes E, Lindon JC, Plumb RS, Nicholson JK, Want EJ. 2011. HILIC-UPLC-MS for exploratory urinary metabolic profiling in toxicological studies. Anal Chem 83: 382-390.
72. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. 2011. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 108: 4523-4530.
73. Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, Baluom M, Grossbard E, Lau DT. 2010. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 38: 1166-1176.
74. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. 2009. The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1: 6ra14.
75. Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ, Jr., Gonzalez FJ, Idle JR. 2008. Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res 170: 1-14.
76. Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ, Jr., Gonzalez FJ, Idle JR. 2009. Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res 172: 42-57.
77. Villas-Boas SG, Koulman A, Lane GA. 2010. Analytical methods from the perspective of method standardization. In: Neilsen J, Jewett MC, editors. Metabolomics: A powerful tool in systems biology. Berlin: Springer. pp 11-52.
78. Waldram A, Holmes E, Wang Y, Rantalainen M, Wilson ID, Tuohy KM, McCartney AL, Gibson GR, Nicholson JK. 2009. Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res 8: 2361-2375.
79. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330: 831-835.
80. Warburg O. 1956. On the origin of cancer cells. Science 123: 309-314.
81. Wikoff WR, Gangoiti JA, Barshop BA, Siuzdak G. 2007. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin Chem 53: 2169-2176.
82. Wilson ID, Nicholson JK. 2009. The role of gut microbiota in drug response. Curr Pharm Design 15: 1519-1523.
83. Wilson ID, Nicholson JK, Castro-Perez J, Granger JH, Johnson KA, Smith BW, Plumb RS. 2005. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res 4: 591-598.
84. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. 2010. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88: 45-51.
85. Wishart DS. 2011. Advances in metabolite identification. Bioanalysis 3: 1769-1782.
86. Yanes O, Woo HK, Northen TR, Oppenheimer SR, Shriver L, Apon J, Estrada MN, Potchoiba MJ, Steenwyk R, Manchester M, Siuzdak G. 2009. Nanostructure initiator mass spectrometry: Tissue imaging and direct biofluid analysis. Anal Chem 81: 2969-2975.
87. Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. 2007. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol 21: 2136-2151.